ZURICH/LONDON (Reuters) – Swiss drugmaker Roche is paying $2.4 billion to buy the rest of Foundation Medicine (FMI) , raising its bet on the U.S. genomic profiling group’s ability to personalize cancer care.
Source:: Reuters – Business News
Newswire
- [ March 18, 2025 ] ABVC BioPharma (NASDAQ: ABVC) CEO Interview with Uttam Patil CEO Interview
- [ March 17, 2025 ] Hyperfine (NASDAQ: HYPR) and NVIDIA Collaborate to Revolutionize Neuroimaging with AI-Powered Innovation Newsmakers
- [ March 13, 2025 ] FDA Issues Clearance for ReWalk 7 Exoskeleton (NASDAQ: LFWD) Newsmakers
- [ March 13, 2025 ] ImmunoPrecise (NASDAQ: IPA)Antibodies and a Global Biotechnology Leader Enter into a USD $8M-$10M Partnership for the Development of Novel Cancer Therapeutics. Newsmakers
- [ March 13, 2025 ] “Pure Play on US Drone Market” Unusual Machines (NYSE: UMAC) CEO Interview with Allan Evans Aerospace & Defense
- [ March 6, 2025 ] Plus Therapeutics (NASDAQ: PSTV) Granted U.S. FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda for the Treatment of Leptomeningeal Metastases in Patients with Lung Cancer Newsmakers
- [ March 3, 2025 ] BioXcel Therapeutics (NASDAQ: BTAI) Announces FDA Closed its Inspection of Site for Phase 3 TRANQUILITY II Trial for Acute Treatment of Agitation Associated with Alzheimer’s Dementia Newsmakers
- [ February 24, 2025 ] PepGen (NASDAQ: PEPG) Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Corporate Highlights Newsmakers
- [ February 18, 2025 ] ScanTech AI (NASDAQ: STAI) Announces Initiative to Combat Contraband in Correctional Facilities Across the Americas Newsmakers
- [ February 18, 2025 ] ProPhase Labs (NASDAQ: PRPH) hires Stuart Hollenshead as COO, the former COO and CBO of Barstool Sports Newsmakers
Copyright 1997-2019 Wall Street Reporter / Octagon Media Corp.